IL22

Summary

IL22 (interleukin 22, HGNC:14900) is a protein-coding gene on chromosome 12q15, encoding Interleukin-22 (Q9GZX6). Cytokine that plays a critical role in modulating tissue responses during inflammation.

This gene is a member of the IL10 family of cytokines that mediate cellular inflammatory responses. The encoded protein functions in antimicrobial defense at mucosal surfaces and in tissue repair. This protein also has pro-inflammatory properties and plays a role in in the pathogenesis of several intestinal diseases. The encoded protein is a crucial cytokine that regulates host immunity in infectious diseases, including COVID-19 (disease caused by SARS-CoV-2).

Source: NCBI Gene 50616 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 47 total
• Druggable target: yes
• MANE Select transcript: NM_020525

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14900
Approved symbol	IL22
Name	interleukin 22
Location	12q15
Locus type	gene with protein product
Status	Approved
Aliases	ILTIF, IL-21, zcyto18, IL-TIF, IL-D110, TIFa, TIFIL-23, IL-22, MGC79382, MGC79384
Ensembl gene	ENSG00000127318
Ensembl biotype	protein_coding
OMIM	605330
Entrez	50616

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000328087, ENST00000538666

RefSeq mRNA: 1 — MANE Select: NM_020525 NM_020525

CCDS: CCDS8982

Canonical transcript exons

ENST00000538666 — 6 exons

Exon	Start	End
ENSE00000920697	68252504	68252647
ENSE00000920698	68252764	68252829
ENSE00001100627	68251513	68251578
ENSE00002202652	68253583	68253604
ENSE00002210960	68253263	68253494
ENSE00002266681	68248242	68248876

Expression profiles

Bgee: expression breadth broad, 57 present calls, max score 78.67.

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	78.67	gold quality
diaphragm	UBERON:0001103	67.15	gold quality
pancreatic ductal cell	CL:0002079	63.42	silver quality
decidua	UBERON:0002450	62.84	gold quality
mucosa of urinary bladder	UBERON:0001259	58.16	gold quality
epithelial cell of pancreas	CL:0000083	58.09	gold quality
cranial nerve II	UBERON:0000941	57.72	silver quality
tibialis anterior	UBERON:0001385	57.36	silver quality
nasal cavity epithelium	UBERON:0005384	53.67	gold quality
vermiform appendix	UBERON:0001154	53.62	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	53.42	gold quality
deltoid	UBERON:0001476	53.37	gold quality
cartilage tissue	UBERON:0002418	53.35	gold quality
quadriceps femoris	UBERON:0001377	53.24	gold quality
triceps brachii	UBERON:0001509	52.90	gold quality
vastus lateralis	UBERON:0001379	52.47	gold quality
pons	UBERON:0000988	52.43	gold quality
hair follicle	UBERON:0002073	52.43	gold quality
caecum	UBERON:0001153	51.81	gold quality
myocardium	UBERON:0002349	51.72	gold quality
heart right ventricle	UBERON:0002080	51.41	gold quality
left ventricle myocardium	UBERON:0006566	51.17	gold quality
cardiac muscle of right atrium	UBERON:0003379	51.07	gold quality
upper arm skin	UBERON:0004263	50.47	gold quality
Brodmann (1909) area 46	UBERON:0006483	50.01	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
bone marrow cell	CL:0002092	49.00	silver quality
kidney epithelium	UBERON:0004819	48.99	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-29	yes	20572.29
E-CURD-89	no	5150.58
E-ANND-3	no	2.92

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AHR, FOXP3, IKZF1, MAF, RORA, RORC, RUNX1, STAT3

miRNA regulators (miRDB)

45 targeting IL22, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-3688-3P	99.97	72.02	2834
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-29B-2-5P	99.67	68.98	1726
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-4261	99.59	70.30	3415
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-203A-3P	99.49	70.56	2806
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-147B-5P	99.45	70.62	2432

Literature-anchored findings (GeneRIF, showing 40)

• Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. (PMID:12087100)
• Data report the crystallographic structure of recombinant human interleukin-22, which has been solved at 2.0 angstrom resolution using the SIRAS method. (PMID:12176383)
• role for IL-22 in the regulation of pulmonary inflammation (PMID:15039135)
• T cell-derived cytokine IL-22 is a survival factor for hepatocytes (PMID:15122762)
• IL-21 contributes to the ongoing Th1 mucosal response in Crohn’s disease. (PMID:15765404)
• IL-22 acts on human colonic subepithelial myofibroblaststo elicit expression of proinflammatory cytokines and matrix-degrading molecules indicating proinflammatory/remodeling roles in inflammatory bowel disease. (PMID:16143135)
• IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and IEC migration. (PMID:16537974)
• IL-22 and the acute phase protein pathway are associated with innate host resistance to HIV infection. (PMID:17182579)
• IL-22 promotes liver cell regeneration by increasing hepatic cell proliferation and hepatocyte migration through the activation of Akt and STAT signaling, which is abrogated by SOCS-1/3 overexpression. (PMID:17204547)
• These data suggest that systemic IL-22 may contribute to the prevention of systemic inflammation provoked by LPS present in the blood of CD patients through its induction of hepatic LBP. (PMID:17442982)
• Genetic variation in IL-10RA/IL-22 genes may play a modulatory role in the outcome of hepatitis C infection. (PMID:17845543)
• Hepatic IL-22 expression is up-regulated in viral hepatitis but IL-22 does not directly regulate antiviral proteins and has, in contrast to IFN-alpha, no effect on HCV replication. (PMID:18191408)
• The role of IL-22 in mucosal immunity against Klebsiella pneumoniae infections is reported. (PMID:18264110)
• Crystallization of the IL-22-IL-22R1 complex may aid in understanding of the structural basis for IL-22-mediated cross-talk between the immune system and epithelial cells. (PMID:18391423)
• demonstrate the importance of the IL-22 autocrine pathway in a lymphoid malignancy, and reveal yet another novel function of NPM-ALK (PMID:18509351)
• Molecular basis for the distinct affinities and specificities of IL-22 and IL-10 receptor chains that regulate cellular targeting and signal transduction to elicit effective immune responses. (PMID:18599299)
• Peripheral blood mononuclear cells from immunocompetent Candida-infected patients secreted more IL-17 and IL-22 than those of both chronic mucocutaneous candidiasis patients and healthy, non-infected controls. (PMID:18615114)
• A 1.9A crystal structure of the IL-22/IL-22R1 complex is reported. (PMID:18675809)
• identifies those amino acid side chains of IL-22 that are individually important for optimal binding to IL-22R (PMID:18675824)
• Up-regulation of interleukin-22 is associated with non-small cell lung carcinoma. (PMID:18927282)
• NK-22 cells provide an innate source of IL-22 that may help constrain inflammation and protect mucosal sites (PMID:18978771)
• A decrease in serum IL-22 levels in patients with SLE suggests that this cytokine may be implicated in the pathomechanisms of this disease. (PMID:19046958)
• stage 3 immature natural killer cells are highly enriched for IL-22 and IL-26 messenger RNA, and IL-22 protein production, but do not express IL-17A or IL-17F (PMID:19244159)
• Comparison of IL-22/IL-22BP and IL-22/IL-22R1 crystal structures shows that both receptors display an overlapping IL-22 binding surface, which is consistent with the inhibitory role played by IL-22 binding protein. (PMID:19285080)
• data demonstrate that IL-22-producing T cells in humans may play an important role in the defense against fungal infections such as C. albicans (PMID:19449309)
• IL-22 gene polymorphisms not significantly associated with the presence or clinical features of chronic plaque psoriasis (PMID:19469905)
• The frequencies of IL-17-positive and IL-22-positive CD4+ T cells were increased in peripheral blood mononuclear cells from patients with ankylosing spondylitis and patients with rheumatoid arthritis. (PMID:19479869)
• Recent studies highlight the importance of regulatory cytokines transforming growth factor-beta, IL-10, and IL-22 in controlling differentiation and function of lymphocytes under steady-state and inflammatory conditions, and minimizing tissue damage. (PMID:19481975)
• IL-17 and IL-22 play complementary roles in human protection against Kala Azar, and that a defect in Th17 induction may increase the risk of Kala Azar. (PMID:19620772)
• Data show that number of peripheral Th17 lymphocytes, expression of CCR6 on Th cells, and ex vivo IL-23, anti-CD3 and anti-CD28 induced production of IL-22 by PBMC were significantly elevated in asthmatic patients. (PMID:19811428)
• Data show that in lesional skin of psoriasis patients, highly elevated IL-20 levels strongly correlated with IL-22, and to a lesser extent, with IL-17A and TNF-alpha. (PMID:19830738)
• NK cells can contribute to immune defenses against M. tuberculosis through production of IL-22. (PMID:19864591)
• identified a subset of Th cells that infiltrates the epidermis inflammatory skin disorders and is characterized by the secretion of IL-22 and TNF-alpha, but not IFN-gamma, IL-4, or IL-17 (PMID:19920355)
• IL-17A+IFN-gamma-, IL-17A+IL-22+IFN-gamma-, and IL-17A+IL-22-IFN-gamma- cells were increased in psoriatics (PMID:20032993)
• Essentially identical phenotypes in transgenic mouse models for IL-20, IL-22, and IL-24 suggest that the three related cytokines play a redundant role in keratinocyte differentiation and proliferation. (PMID:20061404)
• expression enhanced in infiltrating inflammatory cells in the inflamed epithelium in ulcerative colitis mucosa (PMID:20065946)
• Data report a modest but significant elevation of serum IL-22 detectable in abdominal sepsis patients. (PMID:20220564)
• Recent findings on the role of Th17 cells and their associated cytokines (IL-17 and IL-22) in the pathogenesis of liver diseases, are summarized. (PMID:20305686)
• Findings suggest that the rs1179251 SNP in IL-22 is associated with risk of colon cancer. (PMID:20339910)
• IL-22, likely via activation of STAT3 and downstream genes (e.g., SOCS3), is able to protect against cell stretch and pulmonary baro-/biotrauma by enhancing epithelial cell resistibility (PMID:20463292)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il22	ENSMUSG00000074695
mus_musculus	Il22b	ENSMUSG00000090461
rattus_norvegicus	Il22	ENSRNOG00000007365

Protein

Protein identifiers

Interleukin-22 — Q9GZX6 (reviewed: Q9GZX6)

Alternative names: Cytokine Zcyto18, IL-10-related T-cell-derived-inducible factor

All UniProt accessions (2): Q9GZX6, A0A7R8C389

UniProt curated annotations — full annotation on UniProt →

Function. Cytokine that plays a critical role in modulating tissue responses during inflammation. Plays an essential role in the regeneration of epithelial cells to maintain barrier function after injury and for the prevention of further tissue damage. Unlike most of the cytokines, has no effect on immune cells. Signals through a heterodimeric receptor composed of two subunits, the specific receptor IL22RA1 which is present on non-immune cells in many organs and the shared subunit IL10RB. Ligation of IL22RA1 with IL22 induces activation of the tyrosine kinases JAK1 and TYK2, which in turn activates STAT3. In turn, promotes cell survival and proliferation through STAT3, ERK1/2 and PI3K/AKT pathways. Promotes phosphorylation of GSK3B at ‘Ser-9’ and CTTN. Promotes epithelial cell spreading.

Subcellular location. Secreted.

Similarity. Belongs to the IL-10 family.

RefSeq proteins (1): NP_065386* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR009079	4_helix_cytokine-like_core	Homologous_superfamily
IPR020423	IL-10_CS	Conserved_site
IPR020453	IL-22	Family

Pfam: PF14565

UniProt features (19 total): helix 9, glycosylation site 3, disulfide bond 2, signal peptide 1, chain 1, strand 1, turn 1, sequence variant 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
3DLQ	X-RAY DIFFRACTION	1.9
1M4R	X-RAY DIFFRACTION	2
3Q1S	X-RAY DIFFRACTION	2.15
3DGC	X-RAY DIFFRACTION	2.5
1YKB	X-RAY DIFFRACTION	2.6
3G9V	X-RAY DIFFRACTION	2.76

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9GZX6-F1	89.30	0.78

Antibody-complex structures (SAbDab): 1 — 3Q1S

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (2): 40–132, 89–178

Glycosylation sites (3): 54, 68, 97

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8854691	Interleukin-20 family signaling
R-HSA-9725370	Signaling by ALK fusions and activated point mutants

MSigDB gene sets: 327 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_DN, GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, chr4q25, REACTOME_INNATE_IMMUNE_SYSTEM, ZHAN_MULTIPLE_MYELOMA_PR_DN, REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, RORA1_01, FISCHER_G1_S_CELL_CYCLE, GOBP_RESPONSE_TO_CORTICOSTEROID, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GOBP_CANONICAL_NF_KAPPAB_SIGNAL_TRANSDUCTION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN

GO Biological Process (5): acute-phase response (GO:0006953), inflammatory response (GO:0006954), negative regulation of inflammatory response (GO:0050728), response to glucocorticoid (GO:0051384), signal transduction (GO:0007165)

GO Molecular Function (3): cytokine activity (GO:0005125), interleukin-22 receptor binding (GO:0045518), protein binding (GO:0005515)

GO Cellular Component (2): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Signaling by Interleukins	1
Signaling by ALK in cancer	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
acute inflammatory response	1
defense response	1
inflammatory response	1
negative regulation of defense response	1
negative regulation of response to external stimulus	1
regulation of inflammatory response	1
response to corticosteroid	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
receptor ligand activity	1
cytokine receptor binding	1
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2358 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL22	IL22RA1	Q8N6P7	998
IL22	IL10RB	Q08334	997
IL22	IL22RA2	Q969J5	969
IL22	IL17A	Q16552	967
IL22	IL17F	Q96PD4	939
IL22	IL10	P22301	939
IL22	IFNG	P01579	926
IL22	CD4	P01730	914
IL22	IFNL2	Q8IZJ0	894
IL22	IL23A	Q9NPF7	890
IL22	IL20RA	Q9UHF4	867
IL22	IL25	Q9H293	866
IL22	REG3G	Q6UW15	864
IL22	IL6	P05231	860
IL22	STAT3	P40763	858

IntAct

13 interactions, top by confidence:

A	B	Type	Score
IL22RA1	IL22	psi-mi:“MI:0407”(direct interaction)	0.850
IL22	IL22RA1	psi-mi:“MI:0407”(direct interaction)	0.850
IL22	IL10RB	psi-mi:“MI:0915”(physical association)	0.590
IL22	IL22RA2	psi-mi:“MI:0407”(direct interaction)	0.440

BioGRID (9): IL22RA2 (Reconstituted Complex), IL22 (Negative Genetic), NOD2 (Negative Genetic), IL22 (Proximity Label-MS), IL10RB (Affinity Capture-Western), IL22RA1 (Affinity Capture-Western), IL22 (Reconstituted Complex), S100P (Reconstituted Complex), S100A6 (Reconstituted Complex)

ESM2 similar proteins: A0A2R8QHQ6, A0A8M9PDM1, A6PWV3, A6QL94, D3Z690, F5HC71, O02699, O12980, O77515, P04401, P05402, P0DJF3, P0DP43, P12401, P17150, P18917, P19159, P20826, P21583, P21702, P33579, P33580, P46685, P52173, P79169, Q08125, Q14512, Q28586, Q29030, Q4R6V5, Q5VZ72, Q60440, Q62575, Q6AY06, Q6P7N7, Q920I0, Q95J76, Q95MD2, Q95N18, Q9CQ58

Diamond homologs: P55029, Q9GZX6, Q9JJY8, Q9JJY9

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
IL22	up-regulates	IL10RB	binding
IL22	down-regulates	IL22RA2	binding
IL22RA2	up-regulates	IL22	binding
IL22	up-regulates	IL22RA1	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

999 predictions. Top by Δscore:

Variant	Effect	Δscore
12:68251507:TCCTA:T	donor_loss	1.0000
12:68251508:CCTA:C	donor_loss	1.0000
12:68251509:CTA:C	donor_loss	1.0000
12:68251510:TACC:T	donor_loss	1.0000
12:68251511:A:T	donor_loss	1.0000
12:68251512:C:CT	donor_loss	1.0000
12:68251574:ATATG:A	acceptor_gain	1.0000
12:68251575:TATG:T	acceptor_gain	1.0000
12:68251576:ATG:A	acceptor_gain	1.0000
12:68251577:TG:T	acceptor_gain	1.0000
12:68251578:GC:G	acceptor_loss	1.0000
12:68251579:C:CA	acceptor_loss	1.0000
12:68251579:C:CC	acceptor_gain	1.0000
12:68251581:A:C	acceptor_gain	1.0000
12:68252499:CTTA:C	donor_loss	1.0000
12:68252500:TTAC:T	donor_loss	1.0000
12:68252502:A:AC	donor_gain	1.0000
12:68252502:ACAC:A	donor_loss	1.0000
12:68252503:C:CG	donor_gain	1.0000
12:68252503:CA:C	donor_gain	1.0000
12:68252503:CACA:C	donor_gain	1.0000
12:68252503:CACAT:C	donor_gain	1.0000
12:68252514:AG:A	donor_gain	1.0000
12:68252515:G:C	donor_gain	1.0000
12:68252545:C:CT	donor_gain	1.0000
12:68252546:C:CT	donor_gain	1.0000
12:68252550:T:TA	donor_gain	1.0000
12:68252643:CTCAT:C	acceptor_gain	1.0000
12:68252644:TCAT:T	acceptor_gain	1.0000
12:68252645:CAT:C	acceptor_gain	1.0000

AlphaMissense

1190 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:68248853:T:A	K162N	0.996
12:68248853:T:G	K162N	0.996
12:68248805:G:C	C178W	0.990
12:68252613:A:G	L96P	0.987
12:68253309:A:C	F47C	0.987
12:68248806:C:T	C178Y	0.986
12:68248842:T:A	E166V	0.986
12:68248854:T:A	K162I	0.986
12:68248807:A:G	C178R	0.985
12:68252817:C:G	D67H	0.981
12:68248818:A:G	L174P	0.980
12:68252634:C:G	C89S	0.979
12:68252635:A:G	C89R	0.979
12:68252635:A:T	C89S	0.979
12:68252633:G:C	C89W	0.977
12:68252634:C:T	C89Y	0.976
12:68253270:G:T	A60D	0.976
12:68253309:A:G	F47S	0.976
12:68251532:A:G	L148P	0.975
12:68253271:C:G	A60P	0.975
12:68252816:T:A	D67V	0.972
12:68248855:T:C	K162E	0.971
12:68252537:G:C	F121L	0.971
12:68252537:G:T	F121L	0.971
12:68252539:A:G	F121L	0.971
12:68252606:G:C	F98L	0.971
12:68252606:G:T	F98L	0.971
12:68252608:A:G	F98L	0.971
12:68253308:G:C	F47L	0.971
12:68253308:G:T	F47L	0.971

dbSNP variants (sampled 300 via entrez): RS1000297653 (12:68254262 C>A,T), RS1000691546 (12:68249905 C>A,T), RS1000802859 (12:68254820 G>A), RS1001517336 (12:68253254 G>A,T), RS1001645220 (12:68250371 C>T), RS1002377421 (12:68248514 G>C), RS1002651140 (12:68251780 A>G), RS1003194711 (12:68251879 C>T), RS1003245735 (12:68251647 G>A), RS1003542068 (12:68252807 G>A), RS1003866112 (12:68249299 G>A,T), RS1003985952 (12:68254798 G>T), RS1004614448 (12:68251419 A>G), RS1005645717 (12:68252431 A>G), RS1006166147 (12:68255486 C>A)

Disease associations

OMIM: gene MIM:605330 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000311_2	Ulcerative colitis	3.000000e-12
GCST001725_19	Inflammatory bowel disease	9.000000e-32
GCST004866_10	Alopecia areata	4.000000e-07
GCST005951_145	Body mass index	4.000000e-08
GCST007843_7	Rheumatoid arthritis	4.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3712915 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

32 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	increases methylation, increases secretion	2
2-(1’H-indole-3’-carbonyl)thiazole-4-carboxylic acid methyl ester	affects expression, affects secretion	2
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	2
Nickel	increases expression	2
CBP30 compound	decreases expression	1
CDM-3008	decreases expression, decreases reaction	1
TL8-506	affects cotreatment, increases secretion	1
ferulic acid	decreases reaction, increases expression, increases reaction	1
4,4’-bisphenol F	decreases secretion	1
fucoxanthin	decreases expression, decreases reaction	1
betadex	decreases reaction, increases expression, increases reaction	1
tryptanthrine	decreases reaction, increases expression	1
monophosphoryl lipid A	increases secretion	1
saponin QA-21V1	increases secretion	1
6-formylindolo(3,2-b)carbazole	affects expression	1
Qingdai compound	increases expression, decreases reaction	1
bisphenol S	decreases secretion	1
KL001	affects cotreatment, decreases reaction, increases expression, increases phosphorylation	1
Hydrogen Peroxide	increases secretion	1
Latex	increases expression	1
Paraquat	increases expression, increases reaction, decreases reaction	1
Perfume	increases expression	1
Phthalic Acids	increases methylation	1
Piperacillin	increases secretion	1
Poly I-C	affects cotreatment, increases secretion	1
Polychlorinated Biphenyls	increases expression	1
Sodium Hydroxide	affects response to substance	1
Tetrachlorodibenzodioxin	increases secretion	1
Valproic Acid	decreases methylation	1
Dinoprostone	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.